＜2024年＞

Sasaki M, Kato D, Murakami K, Yoshida H, Takase S, Otsubo T, Ogiwara H.
Targeting dependency on a paralog pair of CBP/p300 against de-repression of KREMEN2 in SMARCB1-deficient cancers.
Nat Commun. 2024 15(1):4770.
doi: 10.1038/s41467-024-49063-w. PMID: 38839769; PMCID: PMC11153594.

＜2023年＞

Kanada R, Kagoshima Y, Suzuki T, Nakamura A, Funami H, Watanabe J, Asano M, Takahashi M, Ubukata O, Suzuki K, Aikawa T, Sato K, Goto M, Setsu G, Ito K, Kihara K, Kuroha M, Kohno T, Ogiwara H, Isoyama T, Tominaga Y, Higuchi S, Naito H.
Discovery of DS-9300: A Highly Potent, Selective, and Once-Daily Oral EP300/CBP Histone Acetyltransferase Inhibitor.
J Med Chem. 2023 66(1):695-715.
doi: 10.1021/acs.jmedchem.2c01641. Epub 2022 Dec 26. PMID: 36572866.

＜2022年＞

Kobayashi Y, Takeda T, Kunitomi H, Chiwaki F, Komatsu M, Nagai S, Nogami Y, Tsuji K, Masuda K, Ogiwara H, Sasaki H, Banno K, Aoki D.
Response Predictive Markers and Synergistic Agents for Drug Repositioning of Statins in Ovarian Cancer.
Pharmaceuticals. 2022 15(2):124.
doi: 10.3390/ph15020124. PMID: 35215239; PMCID: PMC8880614.

＜2020年＞

Sasaki M and Ogiwara H*.

Synthetic Lethal Therapy Based on Targeting the Vulnerability of SWI/SNF Chromatin Remodeling Complex-Deficient Cancers.

Cancer Science. 111(3):774-782. 2020 (Review Article)

doi: 10.1111/cas.14311. Epub 2020 Feb 22. PMID: 31955490; PMCID: PMC7060479. 

荻原秀明　

SWI/SNF クロマチンリモデリング複合体欠損がんを対象とした最適化治療

医学のあゆみ. 272：129-138. 2020

 

Sasaki M, Chiwaki F, Kuroda T, Komatsu M, Matsusaki M, Kohno T, Sasaki H, Ogiwara H*.

Efficacy of Glutathione Inhibitors for the Treatment of ARID1A-Deficient Diffuse-Type Gastric Cancers.

Biochem. Biophys. Res. Commun. 522(2): 342-347. 2020

doi: 10.1016/j.bbrc.2019.11.078. Epub 2019 Nov 22. PMID: 31761322.

＜2019年＞

Ogiwara H*., Takahashi K., Sasaki M., Kuroda T., Yoshida H., Watanabe R., Maruyama A., Makinoshima H., Chiwaki F., Sasaki H., Kato T., Okamoto A., Kohno T*.

Targeting the Vulnerability of Glutathione Metabolism in ARID1A-Deficient Cancers.

Cancer Cell. 35:177-190.e8. 2019

doi: 10.1016/j.ccell.2018.12.009. Epub 2019 Jan 24. PMID: 30686770.

Kuroda T, Ogiwara H*, Sasaki M, Tahahashi K, Yoshida H, Kiyokawa T, Sudo K, Tamura K, Kato T, Okamoto A, Kohno T.

Therapeutic preferability of gemcitabine for ARID1A-deficient ovarian clear cell carcinoma.

Gynecol Oncol. 155:489-498. 2019

doi: 10.1016/j.ygyno.2019.10.002. Epub 2019 Oct 8. PMID: 31604667.

＜2018年以前＞

荻原秀明、河野隆志

クロマチンリモデリング遺伝子欠損がんの合成致死性に基づく最適化治療

医学のあゆみ. 266：859-864. 2018

 

Kanke Y, Shimomura A, Saito M, Honda T, Shiraishi K, Shimada Y, Watanabe R, Yoshida H, Yoshida M, Shimizu C, Takahashi K, Totsuka H, Ogiwara H, Hirose S, Kono K, Tamura K, Okamoto A, Kinoshita T, Kato T, Kohno T.

Gene aberration profile of tumors of adolescent and young adult females.

Oncotarget. 9:6228-6237. 2017

 

Ogiwara H., Sasaki M., Mitachi T., Oike T., Higuchi S., Tominaga Y., Kohno T.

Targeting p300 addiction in CBP-deficient cancers causes synthetic lethality via apoptotic cell death due to abrogation of MYC expression

Cancer Discov. 6: 430-445. 2016

 

Alagoz M, Katsuki Y, Ogiwara H, Ogi T, Shibata A, Kakarougkas A, Jeggo P.

SETDB1, HP1 and SUV39 promote repositioning of 53BP1 to extend resection during homologous recombination in G2 cells.

Nucleic Acids Res. 43:7931-744. 2015

 

Amornwichet N, Oike T, Shibata A, Nirodi CS, Ogiwara H, Makino H, Kimura Y, Hirota Y, Isono M, Yoshida Y, Ohno T, Kohno T, Nakano T.

The EGFR mutation status affects the relative biological effectiveness of carbon-ion beams in non-small cell lung carcinoma cells.

Sci Rep. 5: 11305. 2015

 

Oike T., Ogiwara H., Nakano T., Kohno T.

Proposal for a synthetic lethality therapy using the paralog dependence of cancer cells--response.

Cancer Res. 74:4948-4949. 2014

 

Oike T., Komachi M., Ogiwara H., Amornwichet N., Saitoh Y., Torikai K., Kubo N., Nakano T., Kohno, T.

C646, a selective small molecule inhibitor of histone acetyltransferase p300, radiosensitizes lung cancer cells by enhancing mitotic catastrophe.

Radiother Oncol. 111: 222-227. 2014.

 

Kato K., Nakajima K., Ui A., Muto-Terao Y., Ogiwara H., Nakada S.

Fine-tuning of DNA damage-dependent ubiquitination by OTUB2 supports the DNA repair pathway choice.

Mol Cell 53:617-630. 2014

 

Oike T., Ogiwara H., Amornwichet N., Nakano T., Kohno T.

Chromatin-regulating proteins as targets for cancer therapy.

J Radiat Res. 55:613-628. 2014

 

Watanabe R., Ui A., Kanno S., Ogiwara H., Nagase T., Kohno T., Yasui A.

SWI/SNF factors required for cellular resistance to DNA damage include ARID1A and ARID1B and show interdependent protein stability.

Cancer Res. 74:2465-2475. 2014

 

Nakaoku T, Tsuta K, Ichikawa H, Shiraishi K, Sakamoto H, Enari M, Furuta K, Shimada Y, Ogiwara H, Watanabe S, Nokihara H, Yasuda K, Hiramoto M, Nammo T, Ishigame T, Schetter AJ, Okayama H, Harris CC, Kim YH, Mishima M, Yokota J, Yoshida T, Kohno T.

Druggable oncogene fusions in invasive mucinous lung adenocarcinoma.

Clin Cancer Res. 20: 3087-3093. 2014

 

Amornwichet N, Oike T, Shibata A, Ogiwara H, Tsuchiya N, Yamauchi M, Saitoh Y, Sekine R, Isono M, Yoshida Y, Ohno T, Kohno T, Nakano T.

Carbon-ion beam irradiation kills X-ray-resistant p53-null cancer cells by inducing mitotic catastrophe.

PLoS One. 9:e115121. 2014

 

Ui A., Ogiwara H., Nakajima S., Kanno S., Watanabe R., Harata M., Okayama H., Harris C. C., Yokota J., Yasui A., Kohno, T.

Possible involvement of LKB1-AMPK signaling in non-homologous end joining.

Oncogene. 33:1640-1648. 2014

 

Mizukami T., Shiraishi K., Shimada Y., Ogiwara H., Tsuta K., Ichikawa H., Sakamoto H., Kato M., Shibata T., Nakano T., Kohno, T.

Molecular mechanisms underlying oncogenic RET fusion in lung adenocarcinoma.

J Thorac Oncol. 9:622-630. 2014

 

Oike T., Ogiwara H., Tominaga Y., Ito K., Ando O., Tsuta K., Mizukami T., Shimada Y., Isomura H., Komachi M., Kohno T.

A synthetic lethality-based strategy to treat cancers harboring a genetic deficiency in the chromatin remodeling factor BRG1.

Cancer Res. 73:5508-5518. 2013

 

Oike T., Ogiwara H., Nakano T., Yokota J., Kohno T.

Inactivating mutations in SWI/SNF chromatin remodeling genes in human cancer.

Jpn J Clin Oncol. 43:849-855. 2013

 

Ogiwara H., Ui A., Shiotani B., Zou L., Yasui A., Kohno, T.

Curcumin suppresses multiple DNA damage response pathways and has potency as a sensitizer to PARP inhibitor.

Carcinogenesis. 34:2486-2497. 2013

 

Ogiwara H., and Kohno T.

CBP and p300 histone acetyltransferases contribute to homologous recombination by transcriptionally activating the BRCA1 and RAD51 genes.

PLoS One. 7:e52810. 2012

 

Oike T., Ogiwara H., Torikai K.,Nakano T., Yokota J., Kohno T.

Garcinol, a histone acetyltransferase inhibitor, radiosensitizes cancer cells by inhibiting non-homologous end joining.

Int J Radiat Oncol Biol Phys. 84:815-821. 2012

 

Kohno T, Ichikawa H, Totoki Y, Yasuda K, Hiramoto M, Nammo T, Sakamoto H, Tsuta K, Furuta K, Shimada Y, Iwakawa R, Ogiwara H, Oike T, Enari M, Schetter AJ, Okayama H, Haugen A, Skaug V, Chiku S, Yamanaka I, Arai Y, Watanabe S, Sekine I, Ogawa S, Harris CC, Tsuda H, Yoshida T, Yokota J, Shibata T.

KIF5B-RET fusions in lung adenocarcinoma.

Nat Med. 18: 375-377. 2012

 

Ogiwara H., Ui A., Otsuka A., Satoh H., Yokomi I., Nakajima S., Yasui A., Yokota J., Kohno, T.

Histone acetylation by CBP and p300 at double-strand break sites facilitates SWI/SNF chromatin remodeling and the recruitment of non-homologous end joining factors.

Oncogene. 30:2135-2146. 2011

 

Ogiwara H., and Kohno T.

Essential factors for incompatible DNA end joining at chromosomal DNA double strand breaks in vivo.

PLoS One. 6:e28756. 2011

 

Li S, Kanno S, Watanabe R, Ogiwara H, Kohno T, Watanabe G, Yasui A, Lieber MR.

Polynucleotide kinase and aprataxin-like forkhead-associated protein (PALF) acts as both a single-stranded DNA endonuclease and a single-stranded DNA 3' exonuclease and can participate in DNA end joining in a biochemical system.

J Biol Chem. 286:36368-36377. 2011

 

Lan L., Ui A., Nakajima S., Hatakeyama K., Hoshi M., Watanabe R., Janicki S. M., Ogiwara H., Kohno T., Kanno S., Yasui, A.

The ACF1 complex is required for DNA double-strand break repair in human cells.

Mol Cell. 40:976-987. 2010

 

Kohno T., Otsuka A., Girard L., Sato M., Iwakawa R., Ogiwara H., Sanchez-Cespedes M., Minna J.D., Yokota J.

A catalog of genes homozygously deleted in human lung cancer and the candidacy of PTPRD as a tumor suppressor gene.

Genes Chromosomes Cancer. 49:342-352. 2010

 

Ogiwara H., Kohno T., Nakanishi H., Nagayama K., Sato M., Yokota J.

Unbalanced translocation, a major chromosome alteration causing loss of heterozygosity in human lung cancer.

Oncogene. 27:4788-4797. 2008

 

Ohuchi T, Seki M, Branzei D, Maeda D, Ui A, Ogiwara H, Tada S, Enomoto T.

Rad52 sumoylation and its involvement in the efficient induction of homologous recombination.

DNA Repair. 7:879-889. 2008

 

Ogiwara H., Ui A., Kawashima S., Kugou K., Onoda F., Iwahashi H., Harata M., Ohta K., Enomoto T., Seki M.

Actin-related protein Arp4 functions in kinetochore assembly.

Nucleic Acids Res. 35:3109-3117. 2007.

 

Ogiwara H., Ohuchi T., Ui A., Tada S., Enomoto T., Seki M.

Ctf18 is required for homologous recombination-mediated double-strand break repair.

Nucleic Acids Res. 35:4989-5000. 2007

 

Ogiwara H., Ui A., Enomoto T., Seki M.

Role of Elg1 protein in double strand break repair.

Nucleic Acids Res. 35:353-362. 2007

 

Ogiwara H., Enomoto T., Seki M.

The INO80 chromatin remodeling complex functions in sister chromatid cohesion.

Cell Cycle. 6: 1090-1095. 2007

 

Ogiwara H., Ui A., Lai MS., Enomoto T., Seki M.

Chl1 and Ctf4 are required for damage-induced recombinations.

Biochem Biophys Res Commun. 354:222-226. 2007

 

Kawashima S, Ogiwara H, Tada S, Harata M, Wintersberger U, Enomoto T, Seki M.

The INO80 complex is required for damage-induced recombination.

Biochem Biophys Res Commun. 355:835-841. 2007

 

Tomizawa Y, Ui A, Onoda F, Ogiwara H, Tada S, Enomoto T, Seki M.

Rad50 is involved in MMS-induced recombination between homologous chromosomes in mitotic cells.

Genes Genet Syst. 82:157-160. 2007

 

Ui A, Seki M, Ogiwara H, Lai MS, Yamamoto K, Tada S, Enomoto T.

Activation of a novel pathway involving Mms1 and Rad59 in sgs1 cells.

Biochem Biophys Res Commun. 356:1031-1037. 2007

 

Ogiwara H., Ui A., Onoda F., Tada S., Enomoto T., Seki M.

Dpb11, the budding yeast homolog of TopBP1, functions with the checkpoint clamp in recombination repair.

Nucleic Acids Res. 34:3389-3398. 2006

 

Ui A, Seki M, Ogiwara H, Onodera R, Fukushige S, Onoda F, Enomoto T.

The ability of Sgs1 to interact with DNA topoisomerase III is essential for damage-induced recombination.

DNA Repair. 4: 191-201. 2005